- Acquired by InterCure, Sep 2018
About
Canndoc has been pioneering Pharma-Grade cannabis for more than 15 years, providing millions of doses to 40,000 patients. The company demonstrates significant expertise across the entire value chain from research, cultivation, and processing, to product development and advanced GMP clinical trials pipeline initiation. Driven by the mission of meeting patients’ needs and improving their quality of life, Canndoc holds product efficacy to be of paramount importance, delivering Good Manufacturing Practice (GMP) pharma-grade cannabis solutions to achieve better patient health and treatment outcomes. Canndoc's products are held to the highest pharmaceutical standards, meeting global GMP regulatory requirements. The company is focused on validating its clinical significance through clinical trials with hospitals and universities. Canndoc's GMP standard products are prescribed for a range of indications including Neuropathic pain, Relief of pain of cancerous source, Inflammatory bowel disease, Post-traumatic stress disorder, Parkinson’s, and Epileptic seizures.
Headcount over time
Offices
Q&A
- What is CANNDOC Pharma's primary business?
- CANNDOC Pharma develops pharma-grade cannabis products, focusing on research, cultivation, processing, and product development, with a GMP clinical trial pipeline.
- When was CANNDOC Pharma founded?
- CANNDOC Pharma was founded in January 2008.
- Who acquired CANNDOC Pharma and when?
- CANNDOC Pharma was acquired by InterCure in September 2018.
- What is the employee count of CANNDOC Pharma?
- CANNDOC Pharma has 1-10 employees.
- What medical conditions do CANNDOC Pharma's products address?
- CANNDOC Pharma's GMP-standard products are prescribed for conditions such as neuropathic pain, cancer pain, inflammatory bowel disease, post-traumatic stress disorder, Parkinson's disease, and epileptic seizures.
- In which countries are CANNDOC Pharma's products and genetics regulated?
- CANNDOC Pharma's products and genetics comply with regulatory requirements in Europe, Canada, and Israel.
- Who is the CEO of CANNDOC Pharma?
- Alexander Rabinovitch is the CEO of CANNDOC Pharma.
- What is the primary sector of CANNDOC Pharma?
- CANNDOC Pharma's primary sector is Health Tech & Life Sciences.
Team · 14
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | canndoc.com/ |
|---|---|
| linkedin.com/company/13028545 |
Identifiers & details
| Legal name | Canndoc Ltd. |
|---|---|
| Founded | 2008 |
| Employees (exact) | 7 |
| Status reason | Acquired by InterCure on Sep 2018 |
Acquisitions & public offerings
Acquired by InterCure 2018-09
Radar intelligence
Web history (Wayback)
| Domain | canndoc.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|
Israeli Companies Registrar (רשם החברות / ICA)
| Registrar # (ח.פ.) | 514418581 |
|---|---|
| Status | פעילה |
| Corp type | ישראלית חברה פרטית |
| Incorporated | 2010-03-07 |
| Purpose | לעסוק בכל עיסוק חוקי |
| Liability | מוגבלת |
| In violation (unfiled) | no |
| Last annual report | 2024 |
| Active charges / liens | 0 |
| Registry events | 0 |
| Registered address | מדינת היהודים 85 הרצליה |